Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RENAL CANCER

Tailoring treatment in metastatic renal cell carcinoma

The BIONIKK trial is the first prospective biomarker-driven randomized trial in metastatic clear cell renal cell carcinoma. This trial demonstrates the feasibility of using a transcriptomic biomarker that reflects intrinsic disease biology to optimize treatment efficacy and shows that all patients might not require combination treatment.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Demasure, S. et al. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol. 61, 22–29 (2022).

    CAS  Article  Google Scholar 

  2. Escudier, B. et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 706–720 (2019).

    CAS  Article  Google Scholar 

  3. Vano, Y.-A. et al. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(22)00128-0 (2022).

    Article  PubMed  Google Scholar 

  4. Beuselinck, B. et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res. 21, 1329–1339 (2015).

    CAS  Article  Google Scholar 

  5. Verbiest, A. et al. Clear-cell renal cell carcinoma: molecular characterization of IMDC risk groups and sarcomatoid tumors. Clin. Genitourin. Cancer 17, e981–e994 (2019).

    Article  Google Scholar 

  6. Roussel, E. et al. Molecular subtypes and gene expression signatures as prognostic features in fully resected clear cell renal cell carcinoma: a tailored approach to adjuvant trials. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2021.07.005 (2021).

    Article  PubMed  Google Scholar 

  7. Roussel, E. et al. Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncol. 60, 1499–1506 (2021).

    CAS  Article  Google Scholar 

  8. Singla, N. et al. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight 5, e134564 (2020).

    Article  Google Scholar 

  9. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).

    CAS  Article  Google Scholar 

  10. McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eduard Roussel.

Ethics declarations

Competing interests

B.B. has provided input on the ccrcc molecular grouping for the BIONIKK trial. E.R. and M.A. declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roussel, E., Beuselinck, B. & Albersen, M. Tailoring treatment in metastatic renal cell carcinoma. Nat Rev Urol 19, 455–456 (2022). https://doi.org/10.1038/s41585-022-00615-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-022-00615-z

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing